Grade Iii Astrocytoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GRD007 MIFTS: 60	Grade Iii Astrocytoma Categories: Rare diseases, Neuronal diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Grade Iii Astrocytoma

MalaCards integrated aliases for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma ¹² ⁵³ ¹⁵

Anaplastic Astrocytoma ¹² ⁵³ ⁵⁹ ⁵⁵ ⁷³

Grade Iii Astrocytic Tumor ¹²

Astrocytoma, Anaplastic ⁶

Characteristics:

Orphanet epidemiological data:

⁵⁹

anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of eye, brain and other parts of central nervous system

Malignant neoplasm of brain

Malignant neoplasm: Brain, unspecified

Orphanet: ⁵⁹

Rare neurological diseases

External Ids:

Disease Ontology ¹² DOID:3078

MeSH ⁴⁴ D001254

NCIt ⁵⁰ C9477

SNOMED-CT ⁶⁸ 55353007

Orphanet ⁵⁹ ORPHA251589

UMLS via Orphanet ⁷⁴ C0334579

ICD10 via Orphanet ³⁴ C71.9

UMLS ⁷³ C0334579

Sources

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : ⁵³ Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy.

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to glioblastoma and frontal convexity meningioma, and has symptoms including headache, seizures and motor manifestations. An important gene associated with Grade Iii Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Temodar and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are Decreased viability in esophageal squamous lineage and Reduced mammosphere formation

Disease Ontology : ¹² An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Sources

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)

#	Related Disease	Score	Top Affiliating Genes
1	glioblastoma	26.3	CDK4 CDKN2A CDKN2B DMBT1 EGFR IDH2
2	frontal convexity meningioma	11.0	GFAP TP53
3	brain ependymoma	10.9	EGFR TP53
4	gliofibroma	10.9	GFAP TP53
5	brain stem astrocytic neoplasm	10.9	CDKN2A TP53
6	intracranial chondrosarcoma	10.9	IDH2 TP53
7	zika virus infection	10.9	MDM2 TP53
8	protoplasmic astrocytoma	10.8	GFAP IDH2 TP53
9	cerebral convexity meningioma	10.8	GFAP TP53
10	oligoastrocytoma	10.8	GFAP IDH2 MGMT
11	oral leukoplakia	10.8	CDKN2A PCNA TP53
12	suppressor of tumorigenicity 3	10.8	CDKN2A PCNA TP53
13	anal squamous cell carcinoma	10.8	CDKN2A MGMT TP53
14	pleomorphic xanthoastrocytoma	10.8	GFAP MGMT TP53
15	gemistocytic astrocytoma	10.8	GFAP IDH2 PTEN
16	inverted papilloma	10.8	CDKN2A PCNA TP53
17	oropharynx cancer	10.7	CDKN2A EGFR TP53
18	cellular ependymoma	10.7	GFAP TP53
19	basaloid squamous cell carcinoma	10.7	CDKN2A EGFR TP53
20	vulva cancer	10.7	CDKN2A EGFR TP53
21	pre-malignant neoplasm	10.7	CDKN2A EGFR TP53
22	ring chromosome 7	10.7	CDK4 MDM2 TP53
23	necrotizing sialometaplasia	10.7	CDKN2A GFAP TP53
24	mucinous stomach adenocarcinoma	10.7	PTEN VEGFA
25	gastric lymphoma	10.7	PCNA TP53 VEGFA
26	penile cancer	10.7	CDKN2A EGFR TP53
27	central nervous system lymphoma	10.7	CDKN2A MGMT TP53
28	juvenile pilocytic astrocytoma	10.7	CDKN2A GFAP TP53
29	in situ carcinoma	10.7	CDKN2A EGFR TP53
30	bladder squamous cell carcinoma	10.7	CDKN2A PTEN TP53
31	adult medulloblastoma	10.7	GFAP MDM2 TP53
32	periosteal osteogenic sarcoma	10.7	CDK4 MDM2 TP53
33	actinic cheilitis	10.7	MDM2 TP53
34	anaplastic ependymoma	10.7	GFAP MDM2 PTEN
35	cervical adenocarcinoma	10.7	CDKN2A EGFR TP53
36	small cell sarcoma	10.6	CDK4 MDM2 TP53
37	ependymoma	10.6	EGFR GFAP MGMT
38	primary peritoneal carcinoma	10.6	EGFR TP53 VEGFA
39	cellular schwannoma	10.6	CDKN2A MDM2 TP53
40	embryonal sarcoma	10.6	CDK4 MDM2 TP53
41	thyroid lymphoma	10.6	CDKN2A CDKN2B TP53
42	scrotal carcinoma	10.6	CDKN2A CDKN2B TP53
43	inflammatory mfh	10.6	CDK4 GFAP MDM2
44	malignant peritoneal mesothelioma	10.6	CDKN2A EGFR
45	intrahepatic cholangiocarcinoma	10.6	EGFR IDH2 TP53
46	malignant mesenchymoma	10.6	CDK4 MDM2 TP53
47	ischemic fasciitis	10.6	CDK4 CDKN2A MDM2
48	preretinal fibrosis	10.6	GFAP VEGFA
49	breast carcinoma in situ	10.6	EGFR TP53 VEGFA
50	atypical lipomatous tumor	10.6	CDK4 CDKN2A MDM2

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:

Sources

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:

headache, seizures, motor manifestations, sensory manifestations

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in esophageal squamous lineage	GR00235-A	9.7	IDH2 MMP2 OLIG1 PDGFRA PTEN TP53
2	Reduced mammosphere formation	GR00396-S	9.17	IDH2 MDM2 MMP2 PCNA PTEN CDK4

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

⁴⁶ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	mortality/aging	MP:0010768	10.49	VEGFA TP53 CDK4 APOD BSG CDKN2A
2	growth/size/body region	MP:0005378	10.46	VEGFA TP53 PTEN BSG CDKN2A CDK4
3	homeostasis/metabolism	MP:0005376	10.44	TP53 PTEN CDKN2A CDK4 APOD VEGFA
4	cardiovascular system	MP:0005385	10.43	TP53 PTEN VEGFA CDKN2A CDK4 APOD
5	immune system	MP:0005387	10.43	VEGFA TP53 CDKN2A CDK4 BSG DMBT1
6	cellular	MP:0005384	10.42	TP53 PTEN CDKN2A CDK4 VEGFA EGFR
7	behavior/neurological	MP:0005386	10.4	TP53 PTEN CDKN2A CDK4 APOD VEGFA
8	hematopoietic system	MP:0005397	10.39	TP53 PTEN BSG CDKN2A CDK4 VEGFA
9	endocrine/exocrine gland	MP:0005379	10.37	VEGFA TP53 PTEN BSG CDKN2A CDK4
10	digestive/alimentary	MP:0005381	10.35	TP53 PTEN VEGFA CDKN2A CDK4 DMBT1
11	neoplasm	MP:0002006	10.35	VEGFA TP53 CDK4 CDKN2A DMBT1 EGFR
12	nervous system	MP:0003631	10.3	TP53 PTEN CDKN2A CDK4 APOD VEGFA
13	integument	MP:0010771	10.29	TP53 PTEN CDKN2A CDK4 VEGFA EGFR
14	muscle	MP:0005369	10.27	VEGFA TP53 CDKN2A CDK4 GFAP EGFR
15	embryo	MP:0005380	10.25	TP53 PTEN CDKN2A CDK4 VEGFA EGFR
16	liver/biliary system	MP:0005370	10.13	TP53 PTEN BSG CDKN2A CDK4 VEGFA
17	no phenotypic analysis	MP:0003012	10.13	TP53 CDKN2A VEGFA EGFR CDKN2B MGMT
18	limbs/digits/tail	MP:0005371	10.08	TP53 PTEN VEGFA EGFR MDM2 MMP9
19	normal	MP:0002873	10.06	TP53 PTEN CDK4 VEGFA EGFR GFAP
20	reproductive system	MP:0005389	10.03	VEGFA TP53 PTEN BSG CDKN2A CDK4
21	renal/urinary system	MP:0005367	10.02	VEGFA TP53 PTEN CDK4 DMBT1 EGFR
22	pigmentation	MP:0001186	9.91	TP53 PTEN CDKN2A CDK4 EGFR MDM2
23	respiratory system	MP:0005388	9.9	TP53 PTEN VEGFA BSG CDKN2A EGFR
24	skeleton	MP:0005390	9.65	TP53 PTEN CDKN2A VEGFA EGFR MMP2
25	vision/eye	MP:0005391	9.32	TP53 PTEN CDKN2A CDK4 VEGFA EGFR

Sources

Drugs & Therapeutics for Grade Iii Astrocytoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Temodar ¹⁸ ⁴⁹	TEMOZOLOMIDE	Schering-Plough	August 1999
FDA Label: Temodar Disease/s that Drug Treats:refractory anaplastic astrocytoma Indications and Usage: ¹⁸ TEMODAR is an alkylating drug indicated for the treatment of adultpatients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantlywith radiotherapy and then as maintenance treatment. (1.1) Refractory anaplastic astrocytoma patients who have experienceddisease progression on a drug regimen containing nitrosoureaand procarbazine. (1.2) DrugBank Targets: ¹⁶ 1. DNA Mechanism of Action: ¹⁸ Target: DNA Action: alkylizer FDA: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation ofDNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 367)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carmustine

Approved, Investigational

Phase 3,Phase 1,Phase 2,Not Applicable

154-93-8

2578

Lomustine

Approved, Investigational

Phase 3,Phase 2,Phase 1

13010-47-4

3950

Procarbazine

Approved, Investigational

Phase 3,Phase 2,Phase 1

671-16-9

4915

Trioxsalen

Approved

Phase 3,Phase 2,Phase 1

3902-71-4

5585

Temozolomide

Approved, Investigational

Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

85622-93-1

5394

Dacarbazine

Approved, Investigational

Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

4342-03-4

5351166

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Vincristine

Approved, Investigational

Phase 3,Phase 2,Phase 1

2068-78-2, 57-22-7

5978

Bevacizumab

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

216974-75-3

Vorinostat

Approved, Investigational

Phase 2, Phase 3,Phase 1

149647-78-9

5311

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Donepezil

Approved

Phase 3,Phase 2

120014-06-4

3152

Flucytosine

Approved, Investigational

Phase 2, Phase 3,Phase 1

2022-85-7

3366

Fluorouracil

Approved

Phase 2, Phase 3,Phase 1

51-21-8

3385

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Benzocaine

Approved, Investigational

Phase 3,Phase 2,Not Applicable

1994-09-7, 94-09-7

2337

Valproic Acid

Approved, Investigational

Phase 3,Phase 1,Phase 2

99-66-1

3121

Dopamine

Approved

Phase 3,Phase 2,Not Applicable

51-61-6, 62-31-7

681

chloroquine

Approved, Investigational, Vet_approved

Phase 3

54-05-7

2719

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Histamine

Approved, Investigational

Phase 3

75614-87-8, 51-45-6

774

Methylphenidate

Approved, Investigational

Phase 3

113-45-1

4158

Isotretinoin

Approved

Phase 3,Phase 1

4759-48-2

5538 5282379

tannic acid

Approved, Nutraceutical

Phase 3,Phase 2,Not Applicable

Ornithine

Approved, Nutraceutical

Phase 3

70-26-8, 3184-13-2

6262

Tretinoin

Approved, Investigational, Nutraceutical

Phase 3,Phase 1

302-79-4

5538 444795

Semustine

Experimental, Investigational

Phase 3

13909-09-6

Mitolactol

Investigational

Phase 3

10318-26-0

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Dianhydrogalactitol

Investigational

Phase 3

23261-20-3

Alkylating Agents

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Dermatologic Agents

Phase 3,Phase 1,Phase 2,Not Applicable

Dihematoporphyrin Ether

Phase 3,Phase 2,Phase 1

Ether

Phase 3,Phase 2,Phase 1

Photosensitizing Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 2, Phase 3,Phase 3,Phase 1

Angiogenesis Modulating Agents

Phase 2, Phase 3,Phase 3,Phase 1

Central Nervous System Depressants

Phase 3,Phase 1,Phase 2

Antimitotic Agents

Phase 3,Phase 1,Phase 2

Antineoplastic Agents, Phytogenic

Phase 3,Phase 1,Phase 2

Anti-Infective Agents

Phase 3,Phase 2,Phase 1

Antirheumatic Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2,Phase 1

Keratolytic Agents

Phase 3,Phase 1,Phase 2

Cobalt

Phase 3

7440-48-4

104729

Antibodies

Phase 2, Phase 3,Phase 1

Antibodies, Monoclonal

Phase 2, Phase 3,Phase 1

Endothelial Growth Factors

Phase 2, Phase 3,Phase 1

Histone Deacetylase Inhibitors

Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 376)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma	Unknown status	NCT01656980	Phase 3	Carmustine
2	Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas	Unknown status	NCT00003788	Phase 3	carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3	Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas	Completed	NCT00004259	Phase 3	BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
4	Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)	Completed	NCT00335075	Phase 3	Temozolomide;Semustine
5	Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly	Completed	NCT01502241	Phase 3	Temozolomide
6	Radiation Therapy in Treating Patients With Brain Cancer	Completed	NCT00002620	Phase 3	carmustine;chemotherapy;mitolactol
7	Radiotherapy for Malignant Astrocytomas in the Elderly	Completed	NCT00430911	Phase 3	Radiotherapy
8	Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide	Completed	NCT00717210	Phase 3	Temozolomide
9	Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma	Completed	NCT00003916	Phase 3
10	Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma	Completed	NCT01236560	Phase 2, Phase 3	Temozolomide;Vorinostat
11	High Light and Low Light Dose PDT in Glioma	Completed	NCT00118222	Phase 3	porfimer sodium
12	Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma	Completed	NCT00052455	Phase 3	lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
14	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors	Completed	NCT00369785	Phase 3	donepezil hydrochloride;Placebo
15	Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients	Recruiting	NCT02796261	Phase 3	Eflornithine;Lomustine;Lomustine
16	The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma	Recruiting	NCT02414165	Phase 2, Phase 3	Toca FC;Lomustine;Temozolomide
17	A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas	Recruiting	NCT02629757	Phase 3	β-elemene
18	A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Recruiting	NCT01765088	Phase 3	Temozolomide;α-IFN
19	Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma	Recruiting	NCT00887146	Phase 3	concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
20	Phase III Trial of Anaplastic Glioma Without 1p/19q LOH	Active, not recruiting	NCT00626990	Phase 3	temozolomide
21	VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM	Active, not recruiting	NCT03149575	Phase 3	VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
22	International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)	Not yet recruiting	NCT03243461	Phase 3	Temozolomide + Valproic Acid;Temozolomide + Chloroquine
23	Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma	Terminated	NCT00761280	Phase 3	trabedersen;temozolomide;carmustine;lomustine
24	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3	cyproheptadine hydrochloride
25	Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors	Terminated	NCT00031798	Phase 3	methylphenidate hydrochloride
26	Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas	Withdrawn	NCT00003564	Phase 3	Isotretinoin;Procarbazine Hydrochloride
27	Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas	Unknown status	NCT01721577	Phase 1, Phase 2	AXL1717
28	Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma	Unknown status	NCT00004204	Phase 2	temozolomide
29	Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas	Unknown status	NCT00492687	Phase 2	carboplatin;tamoxifen citrate;temozolomide
30	131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma	Unknown status	NCT00114309	Phase 2	131-I-TM-601;131I-TM601
31	A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain	Unknown status	NCT01403311	Phase 2	5-Aminolevuline Acid
32	Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm	Unknown status	NCT00009854	Phase 1, Phase 2	carmustine in ethanol
33	Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma	Completed	NCT00003470	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
34	Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma	Completed	NCT00003537	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
35	Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma	Completed	NCT00301418	Phase 1, Phase 2	Erlotinib
36	A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma	Completed	NCT00606008	Phase 2	Sunitinib Malate
37	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma	Completed	NCT00003621	Phase 2	carmustine;cisplatin;etoposide
38	Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse	Completed	NCT00003775	Phase 2	leflunomide
39	SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)	Completed	NCT00783393	Phase 2	Temozolomide
40	BNCT to Treat Glioma That Has Progressed Following Radiotherapy	Completed	NCT00115440	Phase 1, Phase 2
41	Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma	Completed	NCT00004017	Phase 2
42	Combination Chemotherapy for Patients With Brain Cancer	Completed	NCT00002814	Phase 2	paclitaxel;topotecan hydrochloride
43	Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma	Completed	NCT00409214	Phase 2	LS11 (talaporfin sodium)
44	A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas	Completed	NCT00921167	Phase 2	Bevacizumab/Irinotecan
45	Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma	Completed	NCT01663012	Phase 2	Etirinotecan pegol
46	Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)	Completed	NCT00589875	Phase 2	Valacyclovir
47	Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma	Completed	NCT00008008	Phase 2	cyclophosphamide;thiotepa
48	Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma	Completed	NCT00431561	Phase 2	AP 12009 10 µM;AP 12009 80 µM;temozolomide or PCV
49	Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors	Completed	NCT00667394	Phase 2	MLN-518 (Tandutinib)
50	Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors	Completed	NCT00003475	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Grade Iii Astrocytoma

Sources

Genetic Tests for Grade Iii Astrocytoma

Sources

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

⁴¹

Brain, Spinal Cord, Bone, Bone Marrow, Liver, T Cells, Endothelial

Sources

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

(show top 50) (show all 224)

#	Title	Authors	Year
1	Erratum: Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. ( 29858379 )	Nordfors K....Granberg K.J.	2018
2	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. ( 28870792 )	Clarke J....Omuro A.	2017
3	Benefit with adjuvant chemotherapy in anaplastic astrocytoma. ( 28801187 )	Schiff D.	2017
4	Prognostic value of survivin and DNA topoisomerase III+ in diffuse and anaplastic astrocytomas. ( 28214203 )	Varughese R.K....Torp S.H.	2017
5	Crossed Aphasia in a Patient with Anaplastic Astrocytoma of the Non-Dominant Hemisphere. ( 29299104 )	Prater S....Horner N.	2017
6	Anaplastic astrocytoma with aquaporin-4 positive in CSF: A case report. ( 29390462 )	Liu Y....Huang Y.	2017
7	Retinal Metastases From Anaplastic Astrocytoma. ( 28864383 )	Gokmen O....Senturk S.	2017
8	The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ( 28775924 )	Sethi P....Singh S.	2017
9	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )	Patel D....Markert J.	2016
10	Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiation-Induced Anaplastic Astrocytoma. ( 26185030 )	Mascelli S....Raso A.	2016
11	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )	Patel D.M....Markert J.M.	2016
12	Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case. ( 27656320 )	Gajavelli S....Graber J.	2016
13	Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. ( 27864706 )	Shin J.Y....Diaz A.Z.	2016
14	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( 27994066 )	Chang S....Mehta M.	2016
15	Metachronous spinal metastases from supratentorial anaplastic astrocytoma. ( 25767596 )	Raheja A....Sharma B.S.	2015
16	An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma. ( 26337554 )	Stival A....Sardi I.	2015
17	Anaplastic astrocytoma mimicking herpes simplex encephalitis in 13-year old girl. ( 26272584 )	Talathi S....Gold M.	2015
18	Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. ( 25793136 )	Barajas R.F....Cha S.	2015
19	Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature. ( 26396627 )	Kuo K.L....Liang P.I.	2015
20	Chronic Phase Intracranial Hemorrhage Caused by Ruptured Pseudoaneurysm Induced by Carmustine Wafer Implantation for Insulo-opercular Anaplastic Astrocytoma: A Case Report. ( 26423018 )	Sato K....Kumabe T.	2015
21	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. ( 25962792 )	Reuss D.E....von Deimling A.	2015
22	Somatic BRAF c.1799T&gt;A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. ( 26360803 )	Watanabe Y....Kure S.	2015
23	Malignant trigeminal nerve sheath tumor and anaplastic astrocytoma collision tumor with high proliferative activity and tumor suppressor p53 expression. ( 25386378 )	Kurdi M....Baeesa S.S.	2014
24	Value of perfusion weighted magnetic resonance imaging in the diagnosis of supratentorial anaplastic astrocytoma. ( 25368772 )	Lee K.M....Park B.J.	2014
25	Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination. ( 24368590 )	Ugur H.C....Sunguroglu A.	2014
26	Variability in target delineation for cavernous sinus meningioma and anaplastic astrocytoma in stereotactic radiosurgery with Leksell Gamma Knife Perfexion. ( 25246145 )	SandstrAPm H....Toma-Dasu I.	2014
27	C-terminally truncated form of I+B-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. ( 24473683 )	Avliyakulov N.K....Pope W.B.	2014
28	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. ( 24993250 )	Kizilbash S.H....Buckner J.C.	2014
29	Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. ( 24395350 )	Capdevila L....BalaA+a C.	2014
30	Immediate disappearance of hemifacial spasm after partial removal of ponto-medullary junction anaplastic astrocytoma: case report. ( 25382264 )	Castiglione M....Ferroli P.	2014
31	Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent Grade III astrocytoma. ( 23391098 )	Pizer B....Mallucci C.	2013
32	Anaplastic astrocytoma. ( 23543397 )	Grimm S.A....Pfiffner T.J.	2013
33	Parenchymal anaplastic astrocytoma presenting with visual symptoms due to bilateral optic nerve sheath involvement. ( 23838764 )	Bui K.M....Villano J.L.	2013
34	The SDF-1 3'A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors: a study on Iranian anaplastic astrocytoma and glioblastoma multiforme patients. ( 23335032 )	Moosavi S.R....Hassanshahi G.	2013
35	An infant with prenatally diagnosed congenital anaplastic astrocytoma who remains disease-free after proton therapy. ( 24015049 )	Shin H.J....Kim D.W.	2013
36	Long-term follow-up of surgical treatment of spinal anaplastic astrocytoma in a cat. ( 23428584 )	Tamura S....Uchida K.	2013
37	Heterogeneous nuclear ribonucleoproteins and their interactors are a major class of deregulated proteins in anaplastic astrocytoma: a grade III malignant glioma. ( 23741984 )	Polisetty R.V....Sirdeshmukh R.	2013
38	A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy. ( 24101275 )	Takeshi N....Kaoru K.	2013
39	Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). ( 23228988 )	Shibui S....Nomura K.	2013
40	Cerebellar anaplastic astrocytoma in an adult with neurofibromatosis type 1: case report and review of literature. ( 23670807 )	Brokinkel B....WAPlfer J.	2013
41	Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. ( 23526410 )	Shonka N.A....Gilbert M.R.	2013
42	Anaplastic astrocytoma masquerading as hemorrhagic stroke. ( 23510543 )	Li L....Shi J.	2013
43	Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases. ( 22704562 )	Martens T....Heese O.	2013
44	Intradural, extramedullary anaplastic astrocytoma arising from the first sacral nerve root. ( 24042468 )	Tiebel N....Malzkorn B.	2013
45	The prognosis of anaplastic astrocytoma with radiologic necrosis mimicking glioblastoma. ( 22827635 )	Kim S.D....Jeong E.H.	2013
46	Synchronous osteoclastoma and anaplastic astrocytoma: A case report. ( 24179512 )	Li B....Dai M.	2013
47	Acquired stuttering due to recurrent anaplastic astrocytoma. ( 24252834 )	Peters K.B....Turner S.	2013
48	The genetic landscape of anaplastic astrocytoma. ( 24140581 )	Killela P.J....Yan H.	2013
49	Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. ( 22821382 )	Mascelli S....GarrA" M.L.	2012
50	Expression pattern and prognostic significance of IGFBP isoforms in anaplastic astrocytoma. ( 22547392 )	Kulkarni A....Chandramouli B.A.	2012

Sources

Genes for Grade Iii Astrocytoma

Genes related to Grade Iii Astrocytoma (1 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	TP53	Tumor Protein P53	Protein Coding	434.51	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9839169 1336544 8599254 (more) 8337939 20090216 19876867 7494604 11550308 11355303 10063271 8108140 11504770 12700122 7494603 12389885 10741908 9042164 16875495 1346255 11764090 10666371 9815715 9341929 7536455 8118823 1758878 11051241 9225141 9529927 9370234 8965097 8682593 7477776 8123492 1501894 17917588 15269478 19716156 17721049 17327574 11048299 1686725 16818615 15981097 15659871 10079373 9407934 9049884 9815964 7534015 8397797 19435942 19151620 15175080 11724349 11175638 9485008 9115587 8676433 7582239 7903434 1349850 1886708 9887356 9577364 8583240 15455376 8529218 16776982
2	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial	Protein Coding	31.02	DISEASES inferred ¹⁵
3	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	25.69	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9779706 17721049 15455376 (more) 7549044 17691113 14744281 16936459 18575733 17965865 19346643 1501894 16849758 18945611
4	EGFR	Epidermal Growth Factor Receptor	Protein Coding	24.85	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	17679463 11504770 10029453 (more) 1314448 19127042 8814167 12700122 16618782 8057151 9260461 9677449 19512898 15163002 8965097 20331873 16030116 15913199 11138928 7815080 17907599 12939468 19716156 17327574 16133418 15943037 11048299 17189383 16364761 9407934 8476201 1776845 11431323 15290895 1320666 16008822 16776982 1311022 8583240
5	PTEN	Phosphatase And Tensin Homolog	Protein Coding	24.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	11504770 9690672 19657395 (more) 11355303 10560660 10702383 10096247 15679305 18836294 17504928 12700122 10666371 10433932 11054184
6	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	24.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	14756441 1806058 1668298 (more) 19663312 7609842 8526753 11554096 7518371 1652162 7684178 8082240 17998256
7	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	23.08	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20090216 12968803 19127042 (more) 8712938 9677449 1357920 10736069 7681617 7974802 8529218 8800324
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	23.06	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	7987821 12700122 9000591 (more) 7582239 7534015 12173338 16614947 7497469 10666371 12185811
9	MDM2	MDM2 Proto-Oncogene	Protein Coding	22.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	12700122 12241107 7815080 (more) 9266437 8504413 16319692
10	CDK4	Cyclin Dependent Kinase 4	Protein Coding	22.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	7987821 16319692 9161727
11	DMBT1	Deleted In Malignant Brain Tumors 1	Protein Coding	21.7	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	10433932 12168116
12	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	20.47	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9669344 8616870 10741908 (more) 12777082 15973775 11683943 12702589 18719373 11507079 17318973 15088099 15700836 15175080 16158178
13	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	20.2	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9000591
14	MMP2	Matrix Metallopeptidase 2	Protein Coding	19.72	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	7630025 10896208 11517976 (more) 8521615 9708803 18795327
15	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	19.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	17189383 16319692 17327574 (more) 14730454
16	BSG	Basigin (Ok Blood Group)	Protein Coding	18.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	18795327
17	MMP9	Matrix Metallopeptidase 9	Protein Coding	18.19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	8521611 19657395 10638966 (more) 10845554 9708803
18	APOD	Apolipoprotein D	Protein Coding	17.98	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	16055749 11895042
19	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	12.34	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	14575240 14730454 17917751 (more) 17415208
20	OLIG1	Oligodendrocyte Transcription Factor 1	Protein Coding	8.1	Novoseek inferred ⁵⁵	14730454 14575240

Sources

Variations for Grade Iii Astrocytoma

ClinVar genetic disease variations for Grade Iii Astrocytoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	TP53	NM_000546.5(TP53): c.733G> A (p.Gly245Ser)	single nucleotide variant	Pathogenic	rs28934575	GRCh37	Chromosome 17, 7577548: 7577548
2	TP53	NM_000546.5(TP53): c.733G> A (p.Gly245Ser)	single nucleotide variant	Pathogenic	rs28934575	GRCh38	Chromosome 17, 7674230: 7674230

Sources

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Sources

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.89	CDK4 CDKN2A CDKN2B EGFR GFAP MDM2
2	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.76	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
3	Cellular Senescence (REACTOME) ⁶⁶ Show member pathways Cellular Senescence ⁶⁶ Oxidative Stress Induced Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	13.16	CDK4 CDKN2A CDKN2B MDM2 TP53 VEGFA
4	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	13.01	CDK4 EGFR MDM2 PDGFRA PTEN TP53
5	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.81	CDK4 CDKN2A CDKN2B EGFR PTEN TP53
6	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.77	CDK4 CDKN2A EGFR MDM2 MMP9 PCNA
7	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.75	EGFR MDM2 PDGFRA PTEN TP53
8	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.72	CDK4 MDM2 MGMT PCNA TP53
9	Pathways in cancer ³⁷	12.72	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
10	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.61	CDK4 MMP9 PCNA PTEN TP53 VEGFA
11	Mitotic G1-G1/S phases ⁶⁶ Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶⁶	12.61	CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
12	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.58	EGFR MDM2 MMP2 MMP9 TP53
13	DNA Damage ⁴	12.55	CDK4 CDKN2A MDM2 MGMT PCNA TP53
14	HTLV-I infection ³⁷	12.47	CDK4 CDKN2A CDKN2B PCNA PDGFRA TP53
15	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.46	EGFR MDM2 PDGFRA TP53
16	MicroRNAs in cancer ³⁷	12.45	CDKN2A EGFR MDM2 MMP9 PDGFRA PTEN
17	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.43	CDK4 CDKN2A MDM2 PTEN TP53
18	Cell cycle ¹ ³⁷	12.4	CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
19	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ Cyclin D associated events in G1 ⁶⁶ G1 Phase ⁶⁶ G1-S Phase Transition ⁶⁴ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶⁶	12.37	CDK4 CDKN2A CDKN2B TP53
20	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.37	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
21	Viral carcinogenesis ³⁷	12.34	CDK4 CDKN2A CDKN2B MDM2 TP53
22	Proteoglycans in cancer ³⁷	12.32	EGFR MDM2 MMP2 MMP9 TP53 VEGFA
23	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.28	CDK4 MDM2 PTEN TP53
24	Colorectal Cancer Metastasis ⁶⁴	12.24	EGFR MMP2 MMP9 TP53 VEGFA
25	Cellular senescence (KEGG) ³⁷	12.19	CDK4 CDKN2A CDKN2B MDM2 PTEN TP53
26	AKT Signaling Pathway ⁶⁷	12.18	CDK4 EGFR MDM2 PDGFRA PTEN TP53
27	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.16	EGFR MDM2 MMP2 PTEN
28	Integrated Breast Cancer Pathway ¹	12.16	CDK4 EGFR MDM2 PTEN TP53 VEGFA
29	Fluid shear stress and atherosclerosis ³⁷	12.13	MMP2 MMP9 TP53 VEGFA
30	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.13	CDKN2B EGFR MDM2 PTEN
31	SMAD Signaling Network ⁶⁴	12.11	CDKN2A MDM2 MMP2 TP53 VEGFA
32	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.09	CDK4 EGFR PDGFRA
33	Development IGF-1 receptor signaling ²² Show member pathways Signal transduction AKT signaling ²²	12.08	MDM2 PCNA PTEN TP53
34	Direct p53 effectors ¹	12.07	EGFR MDM2 MMP2 PCNA PTEN TP53
35	Spinal Cord Injury ¹	12.05	CDK4 EGFR GFAP MMP9 TP53
36	DNA Damage Response (only ATM dependent) ¹	12.04	CDKN2A MDM2 PTEN TP53
37	Interleukin-4 and 13 signaling ⁶⁶	12.03	MMP2 MMP9 TP53 VEGFA
38	Senescence and Autophagy in Cancer ¹	11.98	CDKN2A MDM2 PCNA PTEN TP53
39	Small cell lung cancer ³⁷	11.93	CDK4 CDKN2B PTEN TP53
40	Retinoblastoma (RB) in Cancer ¹	11.89	CDK4 MDM2 PCNA TP53
41	Androgen receptor signaling pathway ¹	11.87	EGFR MDM2 PTEN
42	Angiogenesis (CST) ⁴	11.86	MMP2 MMP9 PDGFRA
43	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.82	GFAP OLIG1 OLIG2 PDGFRA VEGFA
44	Validated targets of C-MYC transcriptional activation ¹	11.81	CDK4 MMP9 TP53
45	Glioblastoma Multiforme ⁶⁴	11.8	CDK4 CDKN2A EGFR MDM2 MGMT PDGFRA
46	Platinum drug resistance ³⁷	11.76	CDKN2A MDM2 TP53
47	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.76	CDKN2A MDM2 TP53
48	Central carbon metabolism in cancer ³⁷	11.74	EGFR PDGFRA PTEN TP53
49	AGE/RAGE pathway ¹	11.71	EGFR MMP2 MMP9
50	LPA receptor mediated events ¹	11.7	EGFR MMP2 MMP9

Sources

GO Terms for Grade Iii Astrocytoma

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.97	CDKN2A MDM2 PTEN TP53 VEGFA
2	positive regulation of apoptotic process	GO:0043065	9.93	CDK4 CDKN2A MMP9 PTEN TP53
3	angiogenesis	GO:0001525	9.92	APOD MMP2 PTEN VEGFA
4	multicellular organism development	GO:0007275	9.92	CDK4 DMBT1 EGFR OLIG1 OLIG2 PDGFRA
5	positive regulation of cell proliferation	GO:0008284	9.91	CDK4 EGFR MDM2 PDGFRA PTEN VEGFA
6	positive regulation of cell migration	GO:0030335	9.89	EGFR MMP9 PDGFRA VEGFA
7	extracellular matrix organization	GO:0030198	9.88	BSG GFAP MMP9 PDGFRA
8	response to drug	GO:0042493	9.88	APOD CDK4 MDM2 MGMT PTEN
9	extracellular matrix disassembly	GO:0022617	9.8	BSG MMP2 MMP9
10	protein sumoylation	GO:0016925	9.79	CDKN2A MDM2 PCNA
11	epithelial cell differentiation	GO:0030855	9.78	DMBT1 PCNA VEGFA
12	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.75	MDM2 PCNA TP53
13	cellular response to amino acid stimulus	GO:0071230	9.73	EGFR MMP2 PDGFRA
14	positive regulation of fibroblast proliferation	GO:0048146	9.72	CDK4 EGFR PDGFRA
15	positive regulation of DNA replication	GO:0045740	9.7	EGFR PCNA PDGFRA
16	embryo implantation	GO:0007566	9.69	BSG MMP2 MMP9
17	positive regulation of vascular smooth muscle cell proliferation	GO:1904707	9.67	MDM2 MMP2 MMP9
18	replicative senescence	GO:0090399	9.63	CDKN2A TP53
19	DNA ligation	GO:0006266	9.63	MGMT PCNA
20	cellular response to reactive oxygen species	GO:0034614	9.63	EGFR MMP9 PDGFRA
21	amyloid fibril formation	GO:1990000	9.6	CDKN2A MDM2
22	cellular response to hypoxia	GO:0071456	9.56	MDM2 PTEN TP53 VEGFA
23	negative regulation of apoptotic process	GO:0043066	9.56	EGFR MDM2 MGMT MMP9 PDGFRA PTEN
24	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:0038091	9.4	PDGFRA VEGFA
25	cellular response to actinomycin D	GO:0072717	9.37	MDM2 TP53
26	positive regulation of DNA repair	GO:0045739	9.33	EGFR MGMT PCNA
27	negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	GO:0031658	8.92	CDK4 CDKN2A CDKN2B PTEN

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.72	CDKN2A CDKN2B EGFR PTEN TP53
2	enzyme binding	GO:0019899	9.65	EGFR MDM2 PCNA PTEN TP53
3	identical protein binding	GO:0042802	9.56	EGFR GFAP MDM2 MMP9 PCNA PTEN
4	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.37	CDKN2A CDKN2B
5	disordered domain specific binding	GO:0097718	9.33	CDKN2A MDM2 TP53
6	platelet-derived growth factor receptor binding	GO:0005161	8.8	PDGFRA PTEN VEGFA

Sources

Sources for Grade Iii Astrocytoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia